Navigation Links
A 'Pacman strategy' to boost the immune system to fight cancer
Date:4/12/2011

A molecule that lies dormant until it encounters a cancer cell, then suddenly activates and rouses the body's immune system to fight cancer cells directly, marks the latest step in scientists' efforts to tap the body's own resources to fight the disease.

The developers of the technology at the University of Rochester Medical Center dub it the "Pacman strategy" because it hinges upon molecular machines produced in abundance by tumors to chew through and gobble up particular chains of molecules.

The key feature of the work is a new type of fusion molecule with three parts: a potent immune cell activator; a second molecule to keep that molecule quiescent until it's needed; and a link between the two that gives scientists control over how the two interact.

The overall fusion molecule acts like a tiny anti-cancer grenade: The portion designed to arouse the immune system to attack cancer is inactive until it's freed, an act that occurs when the link between it and its inhibitory counterpart is cleaved by specialized tumor proteins that chew up such molecules.

The work, led by graduate student John Puskas and Professor John Frelinger, Ph.D., was published online recently in the journal Immunology. Puskas, who is defending his doctoral thesis today, is first author of the paper.

In its experiments the team used Interleukin-2 or IL-2, a cytokine or chemical messenger that amplifies the effects of the immune system. IL-2 has been central to the burgeoning field known as cancer immunotherapy; it turns on T cells and natural killer cells that recognize and kill cancer cells. It's approved by the U.S. Food and Drug Administration for the treatment of melanoma and kidney cancer, but it can have serious side effects, limiting its use in patients dramatically. That's largely because it can harm healthy tissue when it's active throughout the body.

"One reason we chose IL-2 is that it's approved and used to treat patients today. If we're able to reduce the toxicity associated with it, perhaps it could be used more broadly," said Frelinger, professor of Microbiology and Immunology.

In experiments using the technology in the lab, the activity of IL-2 in the fusion protein was weak but became 10 to 50 times more biologically active after cleavage. Importantly, in experiments in mice with cancer, tumor growth was inhibited in mice where IL-2 was turned on using the technology compared to mice in which it was not. In many of the treated mice, tumor cells could not be detected after one week.

A key to the technology is the molecular link between IL-2 and its inhibitor. Puskas and Frelinger built that link out of a chain of amino acids building blocks of proteins. Such chains are broken or cleaved constantly in the body by enzymes known as proteases. In these experiments, when the link is broken, IL-2 breaks free from its inhibitor and is suddenly available to activate other immune cells.

Puskas and Frelinger created links that are cleaved by molecules found much more commonly in cancer cells than other cells. For instance, in one set of experiments, they created a link that is broken only by prostate specific antigen, a protease that is found in prostate cancer cells. They also created links that are cleaved by proteases known as MMP2 and MMP9 both examples of matrix metalloproteinases commonly overactive in many types of tumors.

The approach is designed to turn on the immune system powerfully right in the neighborhood of cancer cells, to destroy those cells, but to avoid a system-wide immune response that could cause severe side effects.

Frelinger points out that the new work is quite different from other experimental anti-cancer efforts that have involved fusion proteins. In other fusion protein approaches, the molecules are active throughout the body. In the new work, the cytokine is designed to be active only near tumor cells, an approach designed to reduce unwanted side effects.

"The beauty of this approach is that you can change any part of the molecule you want," said Frelinger, who also has an appointment in the University's James P. Wilmot Cancer Center. "If you want to target a specific type of cancer, you change the protease sequence to tailor it to particular types of tumors. If you want to change the part of the immune system activated, you change the cytokine.

"Our hope is that an approach like this might someday be coupled with other types of therapy, so that the body could initiate and maintain a vigorous immune response to kill tumors."

Other authors besides Puskas and Frelinger include graduate students Denise Skrombolas and Abigail Sedlacek, and faculty members Edith Lord, Ph.D., and Mark Sullivan, Ph.D. The work was supported by the National Institutes of Allergy and Infectious Diseases as well as by Steven and Alison Krausz and F.C. Blodgett.

"John was very brave for taking on this project," said Frelinger. "It really was something that hadn't been attempted before. He did an outstanding job."


'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Scientists devise targeted therapy strategy for rare form of childhood cancer
2. Top scientists unite to develop global scientific strategy Towards An HIV Cure
3. Protective strategy shields primate ovaries from radiation-therapy-induced damage
4. Songbirds strategy for changing its tune could inform rehab efforts
5. Memory training explored as strategy for addiction treatment
6. Selective strategy recommended for CT scans in emergency departments
7. New Drug Strategy Shows Promise Against HIV
8. UNC scientists discover potential strategy to improve cancer vaccines
9. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
10. Testing African couples for HIV is cost-effective prevention strategy
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Cincinnati, OH (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial planning services from offices headquartered in Hamilton County, is ... animal rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull ... business owners in and around central Kansas, is joining the Youth Horizons organization ... the region. , Headquartered in Wichita, Youth Horizons works to empower area children ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students ... have the unique opportunity to get hands-on experience in an emergency medical simulation, ... immersive experience to gain invaluable, real-life medical skills that are critical success in ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Texas , Dec. 8, 2016 ... program that brings leading-edge laboratory services and management ... United States , allowing more doctors and ... health care management solutions. Logo - ... Hospital systems, under pressure to contain ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch die CFDA sowie ... – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the Chinese Congress ... Union Hospital ...
(Date:12/8/2016)... 8, 2016 Dignitana, a world leader in ... Boa® Technology, creator of the award-winning, patented Boa® system, ... with the DigniCap® scalp cooling system. DigniCap® was cleared ... 2015, and is the first medical scalp cooling device ... cooling system features a patented tight-fitting silicone cooling cap ...
Breaking Medicine Technology: